Company intelligence / Profile preview

Sinqi

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Sinqi is a biotechnology company focused on developing next-generation metabolic therapies, particularly targeting the incretin system. The company specializes in the discovery and development of oral small molecule agonists for the GLP-1, GIP, and glucagon receptors. By leveraging its expertise in medicinal chemistry, Sinqi aims to provide more accessible and effective treatments for chronic conditions such as type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). The company's pipeline is currently in the pre-clinical stage, with a focus on optimizing lead candidates for clinical entry.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Sinqi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinqi.

Explore the full profile